PCSA Stock Risk & Deep Value Analysis
Processa Pharmaceuticals Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About PCSA Stock
We analyzed Processa Pharmaceuticals Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PCSA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is PCSA Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
High
Competitive Risk
High
Execution Risk
High
Regulatory Risk
High
What Are the Red Flags for PCSA?
- âš
Negative or inconclusive clinical trial results for PCS6400 or PCS11T
- âš
Highly dilutive financing rounds impacting shareholder value
- âš
Regulatory setbacks or delays from the FDA
- âš
Increased competition in target oncology indications
Unlock PCSA Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Processa Pharmaceuticals Inc (PCSA) Do?
Market Cap
$8.84M
Sector
Healthcare
Industry
Biotechnology
Employees
10
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine, which is in Phase 2 clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 that is in Phase 2B clinical trials for treatment of gastroparesis; and PCS499 for the treatment of glomerular disease. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2017 and is based in Hanover, Maryland.
Visit Processa Pharmaceuticals Inc WebsiteIs PCSA Stock Undervalued?
Unlock the full AI analysis for PCSA
Get the complete DVR score, risk analysis, and more
Does PCSA Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Nascent/Stable (The potential for a moat exists solely through successful clinical development and patent protection; currently not expanded or eroded).
Moat Sources
1 Identified
Highly uncertain and entirely dependent on positive clinical trial outcomes, regulatory approvals, and the strength of patent exclusivity. Without these, the 'moat' of IP is theoretical.
Moat Erosion Risks
- •Clinical trial failures leading to abandonment of drug candidates
- •Development of superior or similar compounds by competitors
- •Patent challenges or expiry reducing exclusivity period
PCSA Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive PCSA Stock Higher?
Near-Term (0-6 months)
- •Q4 2025 Earnings Release (Estimated late March 2026)
- •Updates on ongoing clinical trials for PCS6400 and PCS11T (General, no specific dates)
Medium-Term (6-18 months)
- •Potential Phase 2 clinical data readouts (Estimated H2 2026 - H1 2027)
- •New investigational new drug (IND) applications for additional pipeline candidates
- •Strategic partnership or licensing agreement discussions
Long-Term (18+ months)
- •Initiation of Phase 3 trials for lead candidates (Estimated 2028+)
- •Potential for market approval and commercialization of a drug (Estimated 2030+)
- •Acquisition by a larger pharmaceutical company
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for PCSA?
- ✓
Positive Phase 2 clinical trial data readouts for PCS6400 or PCS11T
- ✓
Announcements of non-dilutive financing or strategic partnerships
- ✓
Significant insider buying activity
- ✓
Any increase in institutional ownership
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PCSA (Processa Pharmaceuticals Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
